A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2001
11/29/2001	WO2001090083A1 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
11/29/2001	WO2001090081A1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
11/29/2001	WO2001090077A1 Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
11/29/2001	WO2001090076A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
11/29/2001	WO2001090074A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a)
11/29/2001	WO2001090070A2 Caspase inhibitors and uses thereof
11/29/2001	WO2001090069A1 Novel calcium receptor active molecules and method for preparing same
11/29/2001	WO2001090068A2 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
11/29/2001	WO2001090064A2 COMPOSITION AND METHOD CONTAINING PRODUCTS EXTRACTED FROM COMMIPHORA Sp. FOR PREVENTION AND TREATMENT OF ABNORMAL CELL GROWTH AND PROLIFERATION IN INFLAMMATION, NEOPLASIA AND CARDIOVASCULAR DISEASE
11/29/2001	WO2001090063A2 Prodrug of an ice inhibitor
11/29/2001	WO2001090051A1 Phenylglycine derivatives
11/29/2001	WO2001090047A1 Novel mmp-2/mmp-9 inhibitors
11/29/2001	WO2001089582A1 Preventives and remedies for pulmonary hypertension
11/29/2001	WO2001089580A1 Systemic and cardiovascular transduction with lentiviral vectors
11/29/2001	WO2001089570A2 Combination of growth hormone secretagogues and antidepressants
11/29/2001	WO2001089569A1 Combinations of enzyme inhibitor-containing preparations and the use thereof
11/29/2001	WO2001089568A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
11/29/2001	WO2001089564A2 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
11/29/2001	WO2001089558A2 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
11/29/2001	WO2001089557A2 Methods for preventing strokes by inducing tolerance to e-selectin
11/29/2001	WO2001089554A2 Treatment of acute coronary syndrome with glp-1
11/29/2001	WO2001089552A1 Modulaton of alpha-6 integrin-mediated responses
11/29/2001	WO2001089543A2 Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion
11/29/2001	WO2001089542A2 Composition for improving the cell protection comprising a lipophilic antioxidant and a hydrophilic antioxidant
11/29/2001	WO2001089538A2 Apoptotic entities for use in treatment of endothelium dysfunction disorders
11/29/2001	WO2001089536A2 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
11/29/2001	WO2001089525A1 Combination of cerivastatin with ace inhibitors and the use thereof in medicaments
11/29/2001	WO2001089520A2 Dehydroascorbic acid formulations and uses thereof
11/29/2001	WO2001089517A2 Inhibition of cell proliferation and matrix synthesis by antioxidants and nad(p)h oxidase inhibitors
11/29/2001	WO2001089507A1 NOVEL FORMULATIONS OF α-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
11/29/2001	WO2001089504A1 Tropolone derivatives and pharmaceutical compositions
11/29/2001	WO2001089501A1 Polymerizable compositions and methods of use
11/29/2001	WO2001089490A1 Dosage of transdermal delivery systems
11/29/2001	WO2001089483A1 Tablets and methods for modified release of hydrophilic and other active agents
11/29/2001	WO2001089451A2 Protease inhibitors
11/29/2001	WO2001070695A8 Pyridine derivatives as inhibitors of p38
11/29/2001	WO2001060835A8 Purine derivatives
11/29/2001	WO2001058935A3 FACTOR VII OR VIIa-LIKE MOLECULES
11/29/2001	WO2001049305A3 Process for obtaining thylakoids from plants, pure thylakoids and use thereof
11/29/2001	WO2001042471A8 Polypeptides and polynucleotides encoding same
11/29/2001	WO2001042272A3 Eplerenone crystalline form exhibiting enhanced dissolution rate
11/29/2001	WO2001041756A8 Method and composition for treatment of ischemic neuronal reperfusion injury
11/29/2001	WO2001040451A3 Masp-3, a complement-fixing enzyme, and uses for it
11/29/2001	WO2001038347A3 Peptides having antiangiogenic activity
11/29/2001	WO2001031007A3 Nucleic acid molecules derived from rat brain and programmed cell death models
11/29/2001	WO2001030780A3 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
11/29/2001	WO2001029018A3 Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use
11/29/2001	WO2001025433A3 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
11/29/2001	WO2001019776A3 Novel derivatives of dicarboxylic acid having pharmaceutical properties
11/29/2001	WO2001003644A9 Pyrazolopyrimidinone derivatives conjugated to thiophene moieties or benzo [fused] 5-membered heterocycles for erectile dysfunction
11/29/2001	WO2000073469A3 Protein kinases
11/29/2001	WO2000055159A3 Substituted aza-oxindole derivatives
11/29/2001	WO2000039114A3 Substituted oximes and hydrazones as neurokinin antagonists
11/29/2001	WO2000038666A3 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
11/29/2001	WO2000010548A3 19-nor-vitamin d3 compounds with calcemic activity
11/29/2001	US20010047090 VANILREP1 polynucleotides and VANILREP1 polypeptides
11/29/2001	US20010047035 Detecton, treatment and monitoring the patient with poor wound healing ability due to diabetes based on measurement of the breakdown product of nitric oxide (NO) in specimens taken from the patient under controlled conditions
11/29/2001	US20010047020 Benzimidazole derivatives, their production and use
11/29/2001	US20010047008 Allosteric adenosine receptor modulators
11/29/2001	US20010047000 E.g., ranolazine
11/29/2001	US20010046993 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists
11/29/2001	US20010046970 Inhibition of selectin binding
11/29/2001	US20010046968 Angiogenesis inhibition; especially administering naltrexone, naloxone, antibody against OGF or OGF receptor, or antisense molecule of OGF- receptor-encoding gene
11/29/2001	US20010046963 Inhibiting cyclooxygenase-2 biosynthesis and Nuclear factor kappa B synthesis; treatment of arthritis and Alzheimer's disease; administering in food
11/29/2001	US20010046958 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
11/29/2001	US20010046956 May contain another compound to treat diabetes, sexual dysfunction, atherosclerosis, insulin resistance, impaired glucose tolerance, hypercholesterolemia or hypertriglyceridemia
11/29/2001	US20010046496 Administering to the human having a disease associated with leukocyte infiltration of mucosal tissues a humanized immunoglobulin or antigen-binding fragment having binidng specificity for alpha 4 beta 7 integrain
11/29/2001	US20010046495 Use of cross-linked, covalently bound urokinase plasminogen activator (scuPAR)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
11/29/2001	US20010046490 Cell surface molecule-induced macrophage activation
11/29/2001	US20010046481 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
11/29/2001	EP1143949A3 19-nor-vitamin d3 compounds with calcemic activity
11/29/2001	DE10123349A1 New N-sulfonylated pipecolic acid derivatives, are matrix metalloprotease inhibitors useful e.g. for treating rheumatism, tumor progression, arteriosclerosis or inflammatory bowel disease
11/29/2001	DE10025949A1 Arzneimittel zur Bekämpfung von Atemdepression Medications to fight respiratory depression
11/29/2001	DE10025890A1 Dosierung von transdermalen Arzneimittelsystemen Dose of transdermal drug delivery systems
11/29/2001	DE10025728A1 Neue Carbamate und Harnstoffe, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten New carbamates and ureas, their preparation and use as endothelin receptor antagonists
11/29/2001	DE10025308A1 Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln Combination of cerivastatin with ACE inhibitors and their use in medicaments
11/29/2001	DE10025238A1 Verwendung substituierter 1-Amino-5-phenylpentan-3-ol- und/oder 1-Amino-6-phenylhexan-3-ol- Verbindungen als Arzneimittel Use of substituted 1-amino-5-phenylpentane-3-ol and / or 1-amino-6-phenylhexane-3-ol compounds as medicaments
11/29/2001	DE10024939A1 Neue Diphenylmethanderivate für Arzneimittel New diphenylmethane derivatives for pharmaceuticals
11/29/2001	CA2808215A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
11/29/2001	CA2429199A1 Drug metabolizing enzymes
11/29/2001	CA2413326A1 Use of baculovirus vectors in gene therapy
11/29/2001	CA2410593A1 Novel mmp-2/mmp-9 inhibitors
11/29/2001	CA2410567A1 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
11/29/2001	CA2410563A1 Methods for preventing strokes by inducing tolerance to e-selectin
11/29/2001	CA2410294A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
11/29/2001	CA2410096A1 Card domain containing polypeptides, encoding nucleic acids, and methods of use
11/29/2001	CA2409991A1 Bispecific immunoglobulin-like antigen binding proteins and method of production
11/29/2001	CA2409868A1 Modulaton of alpha-6 integrin-mediated responses
11/29/2001	CA2409688A1 Method for improving the cell protection
11/29/2001	CA2409430A1 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
11/29/2001	CA2409367A1 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
11/29/2001	CA2408883A1 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
11/29/2001	CA2408783A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	CA2408781A1 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
11/29/2001	CA2408777A1 Dosage of transdermal delivery systems
11/29/2001	CA2408739A1 Novel proteins and nucleic acids encoding same, diagnostic and therapeutic uses
11/29/2001	CA2408727A1 Benzophenones as inhibitors of il-1.beta. and tnf-.alpha.
11/29/2001	CA2408709A1 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
11/29/2001	CA2408562A1 Dehydroascorbic acid formulations and uses thereof
11/29/2001	CA2408141A1 Neurotransmitter transporters

1 ... 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 ... 1595